





Diagnosing
and Managing

ATTR Cardiomyopathy



Cardiac Amyloidosis Diagnosis and Management

Adapted from Kittleson MM, et al. 2023. *J Am Coll Cardiol*.



*Renin-angiotensin system inhibitors and beta blockers should be used cautiously in ATTR-CM.

AL-CM, light chain amyloid cardiomyopathy; ATTR-CM, TTR amyloid cardiomyopathy; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HF, heart failure; NT-proBNP, N-terminal pro B-type natriuretic peptide; sFLC, serum free light chain; SIFE, serum immunofixation electrophoresis; Tc-99m-PYP, technetium 99m pyrophosphate; TTR, transthyretin; UIFE, urine immunofixation electrophoresis.

Adapted from *J Am Coll Cardiol*, Vol 81, Kittleson MM, et al, 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee, Page 1085, Copyright (2023), with permission from Elsevier.

Laboratory Parameters to Aid in ATTR-CM Diagnosis or Management¹⁻⁴

Elevated or rising **NT-proBNP**

Low **serum TTR/prealbumin**

Elevated or rising **troponin (high sensitivity)**

Low or decreasing **eGFR[†]**



Scan the QR code to learn about the warning signs of cardiac amyloidosis



[†]An eGFR decrease from ≥ 45 mL/min to < 45 mL/min indicates advancement in NAC staging score and disease progression.⁴

References:

1. Garcia-Pavia P, et al. *Eur J Heart Fail.* 2021;23(6):895-905.
2. Hanson JLS, et al. *Circ Heart Fail.* 2018;11(2):e004000.
3. Kittleson MM, et al. *J Am Coll Cardiol.* 2023;81(11):1076-1126.
4. Gillmore JD, et al. *Eur Heart J.* 2018;39(30):2799-2806.